Showing results (1-10 of 78) with videos related to
Sort By:
Pageof 8
Journal of the Formosan Medical Association = Taiwan Yi Zhi|January 9, 2009
Utility of adaptive strategy and adaptive design for biomarker-facilitated patient selection in pharmacogenomic or pharmacogenetic clinical development programSue-Jane WangPharmaceutical Statistics|October 25, 2007
Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSISue-Jane WangContemporary Clinical Trials|August 10, 2020
Recent advances in clinical trial design considerations in Thera"nostics"Sue-Jane WangJournal of Biopharmaceutical Statistics|November 9, 2010
Perspectives on the use of adaptive designs in clinical trials. Part I. Statistical considerations and issuesSue-Jane WangJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trialsYuan Ji, Sue-Jane WangJournal of Biopharmaceutical Statistics|January 8, 2014
Standardization for subgroup analysis in randomized controlled trialsRavi Varadhan, Sue-Jane WangBiometrical Journal. Biometrische Zeitschrift|October 21, 2015
Treatment effect heterogeneity for univariate subgroups in clinical trials: Shrinkage, standardization, or elseRavi Varadhan, Sue-Jane WangPharmaceutical Statistics|September 20, 2011
An evidential approach to non-inferiority clinical trialsSue-Jane Wang, Jeffrey D BlumeJournal of Computational Biology : a Journal of Computational Molecular Cell Biology|December 8, 2004
Sample size for identifying differentially expressed genes in microarray experimentsSue-Jane Wang, James J ChenStatistics in Medicine|January 10, 2003
TACT method for non-inferiority testing in active controlled trialsSue-Jane Wang, H M James HungPageof 8